Matthew C. Nicholson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthew C. Nicholson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Andre Mattman
Department of Pathology and Laboratory Medicine University of British Columbia Vancouver Canada
1 shared publication- Anna R. Hayden
Division of Hematology, Department of Medicine University of British Columbia Vancouver BC Canada
1 shared publication David Dix
Division of Hematology, Oncology and Bone Marrow Transplant, Department of Paediatrics University of British Columbia Vancouver BC Canada
1 shared publication- Jeffrey S. Ginsberg
Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada
1 shared publication Leonie Naeije
Division of Hematology, Oncology and Bone Marrow Transplant, Department of Paediatrics University of British Columbia Vancouver BC Canada
1 shared publication- Luke Y. C. Chen
Division of Hematology University of British Columbia Vancouver British Columbia Canada
1 shared publication
Latest Publications
- Open Access
- 1 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2467
Prevention of Venous Thromboembolism in 2020 and Beyond
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.
- 1 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2467
Open AccessPrevention of Venous Thromboembolism in 2020 and Beyond
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.
- Open Access
Etoposide‐based treatment of adult HLH is associated with high biochemical response but poor survival outcomes
Etoposide‐based treatment is the standard of care for adult HLH in many centers, yet there remains a paucity of data regarding treatment outcomes. We conducted a retrospective study of 23 adults treated with etoposide‐based therapy compared to 10 pediatric HLH cases at a single center. At diagnosis, the median serum ferritin was 20,071 µg/L and 937 µg/L in adults and children, respectively; median sIL‐2r was 14,524 U/mL and 4,478 U/mL. Biochemical response to treatment was high, with 21/23 adults achieving >75% reduction in serum ferritin, but one year survival was only 7/21 compared to 7/10 in pediatric cases.
Open AccessEtoposide‐based treatment of adult HLH is associated with high biochemical response but poor survival outcomes
Etoposide‐based treatment is the standard of care for adult HLH in many centers, yet there remains a paucity of data regarding treatment outcomes. We conducted a retrospective study of 23 adults treated with etoposide‐based therapy compared to 10 pediatric HLH cases at a single center. At diagnosis, the median serum ferritin was 20,071 µg/L and 937 µg/L in adults and children, respectively; median sIL‐2r was 14,524 U/mL and 4,478 U/mL. Biochemical response to treatment was high, with 21/23 adults achieving >75% reduction in serum ferritin, but one year survival was only 7/21 compared to 7/10 in pediatric cases.